PD-L1 High Advanced NSCLC: Is Immunotherapy Alone Always Enough?

The immunology of human breast cancer

Dose-reduced thoracic radiotherapy shows promise for older and frail stage III NSCLC patients in randomized trial

This randomized open-label cohort trial by Wei-Xiang Qi and colleagues investigates whether dose-reduced thoracic radiotherapy can mitigate

ClinicalKey

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

14-protein plasma signature predicts lung cancer risk years before diagnosis and identifies candidates for preventive therapy

This article presents a scientific study identifying a 14-protein plasma signature that can predict lung cancer risk more than 5 years befor

14-protein plasma signature predicts lung cancer risk years before diagnosis and identifies candidates for preventive therapy

This article presents a scientific study on lung cancer risk prediction using a 14-protein plasma signature identified through machine learn